CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Nymoen, Dag Andre ^a   Holth, Arild ^a   Falkentha, Thea E Hetland ^a   Tropé, Claes G ^a,b   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Chemotherapy response; Effusions; Ovarian serous carcinoma; Survival

Indexed keywords

CARBOPLATIN; CASPASE 9; DNA DIRECTED DNA POLYMERASE ETA; DNA GLYCOSYLASE MUTY; FAS ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PROTEIN TYROSINE KINASE; TUMOR MARKER; XERODERMA PIGMENTOSUM GROUP A PROTEIN; ABC TRANSPORTER; ABCA13 PROTEIN, HUMAN; CIAPIN1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ABCA13 GENE; ABCA4 GENE; ABCB10 GENE; ADULT; AGED; ARTICLE; BIRC6 GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASP9 GENE; CIAPIN1 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; FAS GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTATIC SEROUS OVARIAN CARCINOMA; MGMT GENE; MUTYH GENE; OVARY CARCINOMA; OVERALL SURVIVAL; POLH GENE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SRC GENE; TBRKB GENE; TREATMENT RESPONSE; XPA GENE; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RNA, MESSENGER;

EID: 84928654871     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0317-1     Document Type: Article

References (37)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Cancer Registry of Norway. Cancer in Norway 2010 -Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2012.
3. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014;89:207-16.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714-26.
5. Davidson B. Ovarian and Primary Peritoneal Carcinoma. In: Davidson B, Firat P, Michael CM, editors. Serous Effusions-Etiology, Diagnosis, Prognosis and Therapy. London: Springer; 2011. p. 167-204.
6. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011;8:2080-8.
7. Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, et al. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecol Oncol. 2012;126:460-5.
8. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem. 2009;55:611-22.
9. Andersen CL, Jensen JL, Orntoft T. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245-50.
10. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
11. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinumbased chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1748-53.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
13. Fekete T, Rásó E, Pete I, Tegze B, Liko I, Munkácsy G, et al. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer. 2012;131:95-105.
14. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998-1009.
15. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105-27.
16. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403-10.
17. Hlavác V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, et al. The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013;14:515-29.
18. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis. 2012;27:187-96.
19. Arai E, Sakamoto H, Ichikawa H, Totsuka H, Chiku S, Gotoh M, et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer. 2014;135:1330-42.
20. Li X, Wu K, Fan D. CIAPIN1 as a therapeutic target in cancer. Expert Opin Ther Targets. 2010;14:603-10.
21. Cai X, Wang J, Xin X. CIAPIN1 nuclear accumulation predicts poor clinical outcome in epithelial ovarian cancer. World J Surg Oncol. 2012;10:112.
22. Sale JE, Lehmann AR, Woodgate R. Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol. 2012;13:141-52.
23. Zhao Y, Biertümpfel C, Gregory MT, Hua YJ, Hanaoka F, Yang W. Structural basis of human DNA polymerase ?-mediated chemoresistance to cisplatin. Proc Natl Acad Sci U S A. 2012;109:7269-74.
24. Dong HP, Kleinberg L, Silins I, Flørenes VA, Trope' CG, Risberg B, et al. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer. 2008;112:84-93.
25. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, et al. Expression of Xeroderma Pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005;103:2313-9.
26. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109-24.
27. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, et al. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014;32:3103-10.
28. Wang L, Chen YJ, Hou J, Wang YY, Tang WQ, Shen XZ, et al. Expression and clinical significance of BIRC6 in human epithelial ovarian cancer. Tumour Biol. 2014;35:4891-6.
29. Le XF, Bast Jr RC. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther. 2011;12:260-9.
30. Etemadmoghadam D, DeFazio A, Beroukhim R, Mermel C, George J, Getz G, et al. AOCS Study Group: integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15:1417-27.
31. Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res. 2010;70:6325-35.
32. Markkanen E, Dorn J, Hübscher U. MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA. Front Genet. 2013;4:18.
33. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137:1976-85.
34. Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY, et al. The Role of MGMT Testing in Clinical Practice A Report of the Association for Molecular Pathology. J Mol Diagn. 2013;15:539-55.
35. Chen SS, Citron M, Spiegel G, Yarosh D. O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy. Gynecol Oncol. 1994;52:172-4.
36. Hevir N, Vouk K, Sinkovec J, Ribic-Pucelj M, Rižner TL. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem Biol Interact. 2011;191:217-26.
37. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Trope' CG. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum Pathol. 2013;44:2449-60.